Please provide your email address to receive an email when new articles are posted on . The VRBPAC voted unanimously to recommend that future COVID-19 vaccines be monovalent. The vote was based on ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Compared with a monovalent vaccine, a fourth dose of a ...
Credit: Getty Images. The monovalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the US. The Food and Drug Administration (FDA) has authorized the use of the mRNA ...
Pfizer/BioNTech’s bivalent COVID-19 booster vaccine, approved in many parts of the world in late 2022, is no more likely than the monovalent version to increase the risk of cardiovascular events, ...
In a recent study posted to the medRxiv* preprint server, researchers investigated whether the second booster dose of monovalent coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) ...
In a recent study posted to the medRxiv* preprint server, researchers examined the effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) booster doses in preventing severe SARS ...
An advisory committee for the Food and Drug Administration on Thursday voted unanimously (21 to 0) to recommend updating COVID-19 vaccines for the 2023-2024 period to be a monovalent formula targeting ...
The Food and Drug Administration on Tuesday altered its authorizations for mRNA-based COVID-19 vaccines, retiring the original monovalent versions entirely, streamlining immunizations for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results